AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

GSK · NYSE · Drug Manufacturers - General

GSK (ADR) (GSK)

Develops specialty medicines and vaccines through immune-system science and advanced technologies.

$50.72

After hours−0.01 (−0.02%)

At close$50.73(−0.69%)

In millions of USD, except per-share figures · converted from GBP at the latest rate

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	10,873	10,746	9,826	10,522	10,692	10,832	10,030	10,658	11,406	11,501	10,181	11,222
Cost of revenue	3,032	3,227	2,629	2,832	3,199	3,415	2,585	2,889	3,013	3,546	2,502	3,024
Gross profit	7,840	7,519	7,197	7,690	7,493	7,417	7,445	7,768	8,393	7,955	7,679	8,198
	5,239	6,754	5,209	5,493	7,241	6,489	4,488	5,069	4,932	5,945	4,619	7,556
Research & development	2,102	2,732	1,914	1,971	1,947	2,710	1,951	2,701	2,254	3,136	2,258	4,626
	3,064	3,574	2,785	3,290	5,071	3,554	2,763	2,856	2,988	3,522	2,828	2,939
General & administrative	3,064	3,574	2,785	3,290	5,071	3,554	2,763	2,856	2,988	3,522	2,828	2,939
Other expenses	73	448	510	232	223	224	−226	−488	−310	−713	−467	−8
Operating income	2,601	765	1,988	2,197	252	929	2,957	2,700	3,460	2,010	3,060	642
	−211	−259	−180	−202	−167	−177	−144	−181	−183	−742	−199	−169
Interest income	32	48	43	32	43	−68	72	67	35	0	29	77
Interest expense	243	368	222	232	208	192	216	246	223	232	223	243
Other non-operating income	−32	52	−41	−31	−41	−15	−72	−64	−40	510	−24	−73
Income before tax	2,390	506	1,808	1,995	85	751	2,813	2,518	3,278	1,268	2,861	472
Income tax expense	343	−25	366	255	−1	83	448	322	416	298	407	−266
Net income from continuing operations	2,047	531	1,443	1,740	87	669	2,365	2,197	2,861	970	2,454	738
Net income	1,954	467	1,396	1,565	−77	553	2,167	1,926	2,686	849	2,318	581
EPS, basic	$0.96	$0.23	$0.69	$0.77	−$0.04	$0.27	$1.07	$0.96	$1.33	$0.43	$1.15	$0.29
EPS, diluted	$0.96	$0.23	$0.67	$0.75	−$0.04	$0.27	$1.04	$0.93	$1.31	$0.41	$1.15	$0.29
Weighted average shares, basic	2,028	2,028	2,035	2,040	2,040	2,041	2,044	2,032	2,017	2,010	2,012	2,007
Weighted average shares, diluted	2,056	2,059	2,057	2,061	2,040	2,073	2,069	2,055	2,051	2,043	2,037	2,031
EBITDA	3,406	1,544	2,763	3,080	1,563	1,493	4,128	4,311	4,485	2,545	3,702	3,771
Depreciation & amortization	773	831	733	853	1,269	550	1,098	1,547	985	1,045	618	3,056
EBIT	2,633	713	2,030	2,227	294	944	3,029	2,764	3,501	1,500	3,084	715